<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482155</url>
  </required_header>
  <id_info>
    <org_study_id>070(I)HO14386</org_study_id>
    <secondary_id>CRO-PK-14-291</secondary_id>
    <nct_id>NCT02482155</nct_id>
  </id_info>
  <brief_title>Ibuprofen (MOMENT ACT ANALGESIC Granules) Pharmacokinetic Study</brief_title>
  <official_title>Pharmacokinetic Study of a Single Oral Administration of MOMENT ACT ANALGESIC Granules for Oral Solution to Healthy Volunteers Under Fasting Conditions Single Centre, Single Dose, Open-label, Bioavailability Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Research S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study was to evaluate the pharmacokinetic (PK) profile of ibuprofen
      after oral administration of a single dose of MOMENT ACT ANALGESIC granules to healthy male
      and female subjects, under fasting conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant (Î»z) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2,z) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lag-time from the dosing time point prior to the first measurable plasma concentration (tlag) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the first ibuprofen plasma concentration of 5 ug/mL (ton5)</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the first ibuprofen plasma concentration of 10 ug/mL (ton10)</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse effects</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibuprofen 400 mg granules, oral solution, single administration under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>ibuprofen 400 mg single dose oral solution</description>
    <arm_group_label>ibuprofen</arm_group_label>
    <other_name>MOMENTACT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent: signed written informed consent before inclusion in the study;

          2. Sex and age: females and males, 18-55 years old both inclusive;

          3. Body Mass Index (BMI): 18.5-30 kg/m2 inclusive;

          4. Vital signs: systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure
             (DBP) 50-89 mmHg, heart rate (HR) 50-90 bpm, measured after 5 min at rest in the
             sitting position;

          5. Full comprehension: ability to comprehend the full nature and purpose of the study,
             including possible risks and side effects; ability to co-operate with the investigator
             and to comply with the requirements of the entire study;

          6. Contraception and fertility (females only): females of child-bearing potential must be
             using at least one of the following reliable methods of contraception:

               1. hormonal oral, implantable, transdermal, or injectable contraceptives for at
                  least 2 months before the screening visit;

               2. a non-hormonal intrauterine device or female condom with spermicide or
                  contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap
                  with spermicide for at least 2 months before the screening visit;

               3. a male sexual partner who agrees to use a male condom with spermicide;

               4. a sterile sexual partner. Female participants of non-child-bearing potential or
                  in post-menopausal status for at least 1 year will be admitted. For all female
                  subjects, pregnancy test result must be negative at screening and day -1.

        Exclusion Criteria:

          1. Electrocardiogram (ECG) 12-leads (supine position): clinically significant
             abnormalities;

          2. Physical findings: clinically significant abnormal physical findings which could
             interfere with the objectives of the study;

          3. Laboratory analyses: clinically significant abnormal laboratory values indicative of
             physical illness;

          4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or
             formulations' ingredients or related drugs, namely non-steroidal anti-inflammatory
             agents (NSAIDs); history of anaphylaxis to drugs or allergic reactions in general,
             which the investigator considers may affect the outcome of the study;

          5. Diseases: history of significant renal, hepatic, gastrointestinal (in particular
             gastroduodenal ulcer and bleeding), cardiovascular, respiratory (in particular
             asthma), skin, haematological, endocrine or neurological diseases that may interfere
             with the aim of the study;

          6. Medications: medications, including over the counter (OTC) medications and herbal
             products for 2 weeks before the start of the study, in particular ibuprofen. Hormonal
             contraceptives for females are allowed;

          7. Investigative drug studies: participation in the evaluation of any investigational
             product in the 3 months before this study, calculated from the first day of the month
             following the last visit of the previous study;

          8. Blood donation: blood donations in the 3 months before this study;

          9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [&gt;1 drink/day for females
             and &gt;2 drinks/day for males, defined according to United States Department of
             Agriculture Dietary Guidelines 2010], caffeine (&gt;5 cups coffee/tea/day) or tobacco
             abuse (&gt;=10 cigarettes/day); daily use of distilled spirits;

         10. Drug test: positive result at the drug test at screening or day-1;

         11. Alcohol test: positive alcohol breath test at day -1;

         12. Diet: abnormal diets (&lt;1600 or &gt;3500 kcal/day) or substantial changes in eating habits
             in the 4 weeks before this study, vegetarians;

         13. Pregnancy (females only): positive or missing pregnancy test at screening or day -1,
             pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milko Radicioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Research S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CROSS Research S.A., Phase I Unit, Via F.A. Giorgioli 14 Phone: Fax: +41.91.63.00.511 Email:</name>
      <address>
        <city>Arzo</city>
        <zip>CH-6864</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>MOMENTACT</keyword>
  <keyword>ibuprofen 400 mg</keyword>
  <keyword>oral</keyword>
  <keyword>granules</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

